E-LIB Suche - Ergebnisse für: Man, Choy

1

Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Diso..:

Underwood, Mark ; Urbaityte, Rimgaile ; Wang, Ruolan...
Viruses. 16 (2024) 3 - p. 405 , 2024

Link: https://doi.org/10.3390/..

2

1267. Efficacy and Safety of Switching to DTG/3TC in Virolo..:

Prakash, Manyu ; Grove, Richard ; Wynne, Brian R...
Open Forum Infectious Diseases. 9 (2022) Supplement_2 - p. , 2022

Link: https://doi.org/10.1093/..

3

Efficacy and Safety of Switching to the 2-Drug Regimen Dolu..:

Llibre, Josep M ; Brites, Carlos ; Cheng, Chien-Yu...
Clinical Infectious Diseases. 76 (2022) 4 - p. 720-729 , 2022

Link: https://doi.org/10.1093/..

4

EFICÁCIA DURADOURA DE DOLUTEGRAVIR (DTG) E LAMIVUDINA (3 TC..:

Cahn, Pedro ; Madero, Juan Sierra ; Arribas, José Ramón...
The Brazilian Journal of Infectious Diseases. 25 (2021) - p. 101259 , 2021

Link: https://doi.org/10.1016/..

5

Impact of treatment adherence on efficacy of dolutegravir p..:

Ait-Khaled, Mounir ; Sierra Madero, Juan ; Estrada, Vicente...
HIV Research & Clinical Practice. 23 (2021) 1 - p. 9-14 , 2021

Link: https://doi.org/10.1080/..

6

1024. Impact of Treatment Adherence on Efficacy of DTG/3TC ..:

Ait-Khaled, Mounir ; Man, Choy ; Sievers, Jorg...
Open Forum Infectious Diseases. 7 (2020) Supplement_1 - p. S541-S542 , 2020

Link: https://doi.org/10.1093/..

7

Dolutegravir plus lamivudine versus dolutegravir plus tenof..:

Cahn, Pedro ; Madero, Juan Sierra ; Arribas, José Ramón...
The Lancet. 393 (2019) 10167 - p. 143-155 , 2019

Link: https://doi.org/10.1016/..

8

NÃO INFERIORIDADE DE EFICÁCIA DE DOLUTEGRAVIR (DTG) MAIS LA..:

Cahn, Pedro ; Sierra‐Madero, Juan ; Arribas, Jose...
The Brazilian Journal of Infectious Diseases. 22 (2018) - p. 56-57 , 2018

Link: https://doi.org/10.1016/..

9

Metrics and Perspectives on Implementation of the Electroni..:

Brennan, Clare ; Whillis, Hannah ; Man, Choy..
Open Forum Infectious Diseases. 3 (2016) suppl_1 - p. , 2016

Link: https://doi.org/10.1093/..

10

Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) ..:

Hagins, Debbie ; Dietz, Craig ; Jain, Mamta...
Open Forum Infectious Diseases. 3 (2016) suppl_1 - p. , 2016

Link: https://doi.org/10.1093/..

11

Dolutegravir/Lamivudine Efficacy and Safety Outcomes in Peo..:

Scholten, Stefan ; Cahn, Pedro ; Portilla, Joaquín...
Open Forum Infectious Diseases. 11 (2024) 7 - p. , 2024

Link: https://doi.org/10.1093/..

12

EFICÁCIA DURADOURA DE DOLUTEGRAVIR MAIS LAMIVUDINA NO TRATA..:

Porteiro, Norma ; Cahn, Pedro ; Madero, Juan Sierra...
The Brazilian Journal of Infectious Diseases. 26 (2022) - p. 102125 , 2022

Link: https://doi.org/10.1016/..

13

Three-year durable efficacy of dolutegravir plus lamivudine..:

Cahn, Pedro ; Sierra Madero, Juan ; Arribas, José R....
AIDS. 36 (2021) 1 - p. 39-48 , 2021

Link: https://doi.org/10.1097/..

14

Brief Report: Virologic Response by Baseline Viral Load Wit..:

Eron, Joseph ; Hung, Chien-Ching ; Baril, Jean-Guy...
JAIDS Journal of Acquired Immune Deficiency Syndromes. 84 (2020) 1 - p. 60-65 , 2020

Link: https://doi.org/10.1097/..

15

2842. Durable Efficacy of Two-Drug Regimen (2DR) of Doluteg..:

van Wyk, Jean A ; Man, Choy Y ; Sievers, Jörg...
Open Forum Infectious Diseases. 6 (2019) Supplement_2 - p. S67-S68 , 2019

Link: https://doi.org/10.1093/..